As Scarce As…
Twenty Five. That's it. What are we talking about? Some of the data in yesterday's excellent post by Bruce Booth on Early Stage Venture Scarcity really caught us by surprise. What…
Menu
Small Molecule PEGylation: An Idea Ready For Prime Time
At Lacerta Bio, we're big believers in the therapeutic benefits of drug delivery in its many forms. Today, another drug delivery effort earned an FDA approval. In this case, it's…
Combination Products: Is A Different Regulatory Approach Needed?
This morning, California-based Avanir Pharmaceuticals announced that their combination of dextromethorphan HBr and quinidine sulfate (AVP-923) hit their Phase II endpoints in Alzheimer's Disease: Treatment with AVP-923 was associated…
White Paper: Six Considerations When Developing a Biosimilar Strategy
Thompson Reuters published a good overview of the challenges facing companies developing biosimilars. A few items which stood out for us were: Europe Has Led, But... - While 17…
BIO Latin America Webinar: Comments and Perspectives
A few weeks ago, BIO conducted an interesting panel discussion as part of their run up to the BIO Latin America Conference taking place the week in Brazil. The…
Lacerta Bio at BIO Europe 2014
Lacerta Bio is pleased to return to Europe for the 20th Anniversary of the BIO-Europe conference. We will be there from Sunday evening through Wednesday afternoon. Look for us in PartneringOne,…